Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $14.6 million.

  • Corcept Therapeutics' Cash from Investing Activities rose 13325.69% to $14.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.2 million, marking a year-over-year increase of 11793.21%. This contributed to the annual value of -$177.6 million for FY2024, which is 29537.1% down from last year.
  • As of Q3 2025, Corcept Therapeutics' Cash from Investing Activities stood at $14.6 million, which was up 13325.69% from $70.1 million recorded in Q2 2025.
  • Corcept Therapeutics' Cash from Investing Activities' 5-year high stood at $207.5 million during Q1 2023, with a 5-year trough of -$109.6 million in Q3 2023.
  • Moreover, its 5-year median value for Cash from Investing Activities was -$9.0 million (2024), whereas its average is $879052.6.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first soared by 115196.97% in 2021, then crashed by 218747.39% in 2023.
  • Quarter analysis of 5 years shows Corcept Therapeutics' Cash from Investing Activities stood at $140.5 million in 2021, then tumbled by 112.27% to -$17.2 million in 2022, then soared by 199.17% to $17.1 million in 2023, then crashed by 476.42% to -$64.4 million in 2024, then skyrocketed by 122.75% to $14.6 million in 2025.
  • Its Cash from Investing Activities stands at $14.6 million for Q3 2025, versus $70.1 million for Q2 2025 and -$3.2 million for Q1 2025.